Semaglutide and GLP-1 analogues as weight-loss agents

Affiliations

¹ Baylor Heart and Vascular Institute, Dallas, TX 75226, USA; Baylor Scott and White Research Institute, Dallas, TX, USA.
² Baylor Heart and Vascular Institute, Dallas, TX 75226, USA; Baylor Scott and White Research Institute, Dallas, TX, USA; Baylor University Medical Center, Dallas, TX, USA; Baylor Jack and Jane Hamilton Heart and Vascular Hospital, Dallas, TX, USA. Electronic address: peteramccullough@gmail.com.

Comment

Aaron Y Kluger et al. Lancet. 2018.

. 2018 Aug 25;392(10148):615-616.

doi: 10.1016/S0140-6736(18)31826-9. Epub 2018 Aug 16.

¹ Baylor Heart and Vascular Institute, Dallas, TX 75226, USA; Baylor Scott and White Research Institute, Dallas, TX, USA.
² Baylor Heart and Vascular Institute, Dallas, TX 75226, USA; Baylor Scott and White Research Institute, Dallas, TX, USA; Baylor University Medical Center, Dallas, TX, USA; Baylor Jack and Jane Hamilton Heart and Vascular Hospital, Dallas, TX, USA. Electronic address: peteramccullough@gmail.com.

No abstract available

Comment on

Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
O'Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, Carson CG, Jepsen CH, Kabisch M, Wilding JPH. O'Neil PM, et al. Lancet. 2018 Aug 25;392(10148):637-649. doi: 10.1016/S0140-6736(18)31773-2. Epub 2018 Aug 16. Lancet. 2018. PMID: 30122305 Clinical Trial.